The pharmacokinetics (PK) of ADCs typically show a discrepancy between the PK of total antibody (conjugated and unconjugated antibody) and that of conjugated antibody, carrying one or more payload molecules. This discrepancy is often attributed to deconjugation, however recent evidence suggests that the underlying mechanisms may be more complex
This work employs a computational systems pharmacology approach to understand the impact of drug antibody ratio (DAR) and the resulting changes in molecular properties on overall PK and relative payload disposition as observed in preclinical and clinical studies. Our work establishes the benefit of using computational models to design novel ADCs and to optimize the discovery and development of existing ADCs.
- Longer mAb half-life reduces payload delivery after multiple doses
- ADC half-life affects the percent of payload delivered through different mechanisms, with deconjugation increasing with longer half-life.